Verici Dx plc

("Verici Dx" or the "Company")

Board Changes

Aubrey Powell appointed as Non-executive Director

Verici Dx plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect.

Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations.

Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance.

Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals.

Aubrey Powell, Non-executive Director of Verici Dx plc

Julian Baines, MBE, Non-executive Chairman of Verici Dx, said:

"On behalf of the Board, I would like to thank Erik for his contribution to the Company over the last five years, supporting us through our AIM IPO and the transition to a business building commercial scale."

"I am delighted to welcome Aubrey to the Board, and know from first-hand experience just how important his knowledge and expertise can be for AIM quoted growth companies in the healthcare space. Aubrey knows the Verici Dx business well, having previously acted as the lead member of the advisory team at our NOMAD, Singer Capital Markets, and we know that his guidance and challenge, as we enter a pivotal stage in the Company's growth, will be invaluable."

Additional Disclosures Required under the AIM Rules for Companies

In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship:

·    Aubrey Powell Consulting (APC) Limited

Previous directorships or partnerships of which the director has been a director or partner over the last five years:

·    Apus Sequestration LLP

·    Maia Green LLP

Mr Powell holds no shares in the Company.

There is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.